SCHEMBL3242223

SCHEMBL3242223

Cc1ccc(C(=O)NC(c2ccccc2)C(C)(C)N2CCCC2C)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.40
ITGB3 P05106 3/20 0.39
ITGA2B P08514 3/20 0.39
CACNA2D1 P54289 1/20 0.38
CACNA1B Q00975 1/20 0.38
CACNB1 Q02641 1/20 0.38
ALDH1A1 P00352 3/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GLA P06280 1/20 0.38
MCL1 Q07820 1/20 0.38
KCNK3 O14649 5/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
RAB9A P51151 2/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TAS1R2 Q8TE23 1/20 0.36
LMNA P02545 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3237083 0.92 POLB (0.42) ITGB3ITGA2BALDH1A1KDM4EKCNK3
SCHEMBL3243976 0.89 LMNA (0.40) ITGB3ITGA2BALDH1A1KMT2ALMNA
SCHEMBL3232907 0.88 ALDH1A1 (0.39) ITGB3ITGA2BALDH1A1KDM4ESMN1; SMN2
SCHEMBL3240097 0.83 SLC6A9 (0.46) ALDH1A1KDM4ESMN1; SMN2LMNAL3MBTL1
SCHEMBL3244796 0.83 TAS1R3 (0.44) ITGB3ITGA2BALDH1A1KMT2AMAPT
SCHEMBL3238743 0.83 KMT2A (0.45) NPC1ITGB3ITGA2BCACNA2D1CACNA1B
SCHEMBL3236750 0.81 ALDH1A1 (0.39) ITGB3ITGA2BALDH1A1KMT2AKDM4E
SCHEMBL13631388 0.81 RAB9A (0.51) KMT2AMAPTSMN1; SMN2RAB9ALMNA
SCHEMBL3245182 0.81 HPGD (0.45) ALDH1A1KMT2AMAPTLMNA
SCHEMBL3238447 0.79 SLC6A9 (0.40) ALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 NPC1 135/4885ITGB3 4848/4885ITGA2B 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.